Table 4.
Clinical characteristics of patients receiving systemic chemotherapy.
| Chemotherapy | ≥ 6 cycles (29) | < 6 cycles (63) | P | ≥ 3 cycles (37) | < 3 cycles (55) | P |
|---|---|---|---|---|---|---|
| Age (years) | 63.7±11.1 | 65.1±10.8 | 0.560 | 63.0±10.8 | 65.8±10.8 | 0.230 |
| Gender (male : female) | 17 : 12 | 42 : 21 | 0.559 | 21 : 16 | 38 : 17 | 0.226 |
| Body mass index (kg/m2) | 23.81 ± 4.01 | 22.44 ± 3.23 | 0.083 | 23.32 ± 3.94 | 22.57 ± 3.23 | 0.315 |
| ICG, (%) | 12.10 ± 6.46 | 8.11 ± 4.24 | 0.001 | 10.89 ± 6.25 | 8.29 ± 4.44 | 0.022 |
| T-Bil, (mg/dL) | 0.710 ± 0.214 | 0.729 ± 0.250 | 0.736 | 0.716 ± 0.222 | 0.727 ± 0.251 | 0.829 |
| AST, (U/L) | 33.41 ± 23.11 | 23.29 ± 8.30 | 0.003 | 31.19 ± 21.09 | 23.31 ± 8.48 | 0.015 |
| ALT, (U/L) | 26.07 ± 19.61 | 18.89 ± 8.18 | 0.015 | 24.14 ± 17.83 | 19.15 ± 8.55 | 0.076 |
| ALP, (U/L) | 342.17±180.52 | 278.93±109.89 | 0.041 | 341.14±174.80 | 270.43 ± 99.07 | 0.015 |
| Prothrombin time, (%) | 106.31 ± 12.19 | 96.16 ± 11.26 | <0.001 | 104.19 ± 11.97 | 96.11 ± 11.75 | 0.002 |
| Albumin, (g/dL) | 3.92 ± 0.46 | 4.11 ± 0.40 | 0.041 | 4.016 ± 0.43 | 4.08 ± 0.42 | 0.457 |
| CRP, (mg/dL) | 0.397 ± 0.659 | 0.931 ± 1.95 | 0.543 | 0.440 ± 0.728 | 0.628 ± 2.06 | 0.595 |
| Maximum size of tumor diameter (cm) | 3.35 ± 1.95 | 3.71 ± 2.34 | 0.471 | 3.84 ± 2.47 | 3.43 ± 2.04 | 0.383 |
| No. of tumors | 2.72 ± 2.46 | 2.43 ± 2.25 | 0.571 | 2.84 ± 2.30 | 2.31 ± 2.31 | 0.529 |
| Major hepatectomy, (case) (%) | 11, 37.9 | 24, 38.1 | 0.988 | 16, 43.2 | 19, 34.5 | 0.399 |
| Operation time, (min) | 412.5 ± 153.5 | 359.5 ± 126.1 | 0.095 | 399.5 ± 141.5 | 359.8 ± 131.5 | 0.182 |
| Bleeding, (ml) | 1400.6±1410.23 | 1590.8±1169.3 | 0.408 | 1353.2±1375.9 | 1154.0±1156.7 | 0.465 |
| Complication, (case) (%) (Clavian- Dindo classification ≥ 2) |
4, 13.8 | 12, 19.0 | 0.382 | 5, 13.5 | 11, 20.0 | 0.421 |